• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CORDIS CORPORATION CYPHER SIROLIMUS-ELUTING CORONARY STENT; DRUG-ELUTING STENT (NIQ)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CORDIS CORPORATION CYPHER SIROLIMUS-ELUTING CORONARY STENT; DRUG-ELUTING STENT (NIQ) Back to Search Results
Catalog Number CJSXXXX
Device Problem Failure To Adhere Or Bond (1031)
Patient Problem Thrombosis (2100)
Event Date 07/29/2015
Event Type  Injury  
Manufacturer Narrative
Sato, a et al (2015, july, 29).Efficacy of endeavor zotarolimus eluting stent implantation for the treatment of very late stent thrombosis with late acquired incomplete stent apposition after sirolimus eluting stent implantation.Heart vessels.Complaint conclusion: a reported in the article ¿efficacy of endeavor zotarolimus eluting stent implantation for the treatment of very late stent thrombosis with late acquired incomplete stent apposition after sirolimus eluting stent implantation¿, one patient developed thrombus within a previously implanted cypher stent.This occlusion was also associated with positive remodeling and late-acquired incomplete stent apposition with thrombus.The patient was treated with thrombectomy, balloon angioplasty and the placement of a non-cordis drug eluting stent (des) with no further reported patient injury.The event involved a (b)(6) male patient who presented with chest pain and underwent successful cypher stent implantation in his left circumflex artery.Four years after the index procedure, the patient underwent coronary angiography that revealed thrombosis within the previously implanted cypher stent.Further diagnostic testing with intravascular ultrasound revealed positive remodeling and late-acquired incomplete stent apposition with thrombus.The patient was treated with thrombectomy, balloon angioplasty and the placement of a non-cordis des.Follow up angiography eighteen months later revealed no significant in-stent restenosis; while optical coherence tomography revealed sufficient neointimal proliferation with the non-cordis des struts.The product was not returned for analysis.A review of the manufacturing records could not be conducted without a product lot number.Without the return of the device for analysis, the reported ¿stent ¿ underexpanded¿ and ¿thrombosis in device¿ events could not be confirmed and no determination of possible contributing factors could be made.According to the instructions for use, potential adverse events associated with the implantation of this product include, but are not limited to, events such as occlusion, restenosis and thrombosis.Based on the limited information available for review, it is not possible to determine what factors may have contributed to the reported issue.Without a lot number to conduct a device history record review, it is not possible to determine if the reported failure could be related to the manufacturing process.Therefore no corrective and preventive actions will be taken at this time.
 
Event Description
As reported in a publication, efficacy of endeavor zotarolimus eluting stent implantation for the treatment of very late stent thrombosis with late acquired incomplete stent apposition after sirolimus eluting stent implantation.A (b)(6) man presented to the emergency department with chest pain.An ses had been implanted in his left circumflex artery 4 years earlier.Cag revealed total ses occlusion attributed to vlst.Ivus showed positive remodeling and late-acquired incomplete stent apposition.Following thrombectomy and balloon dilatation, an endeavor zes was implanted.Cag 18 months later showed no significant in-stent restenosis.Optical coherence tomography (oct) revealed sufficient neointimal proliferation on the zes struts.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CYPHER SIROLIMUS-ELUTING CORONARY STENT
Type of Device
DRUG-ELUTING STENT (NIQ)
Manufacturer (Section D)
CORDIS CORPORATION
14201 nw 60th avenue
miami lakes FL
Manufacturer Contact
cecil navajas
circuito interior norte #1820
juarez chihuahua 32580
MX   32580
7863133880
MDR Report Key5038427
MDR Text Key24372907
Report Number9616099-2015-00397
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
NA
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type literature
Reporter Occupation Health Professional
Report Date 08/05/2015
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received08/28/2015
Is this an Adverse Event Report? No
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberCJSXXXX
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received08/05/2015
Is the Device Single Use? Yes
Type of Device Usage N
Patient Sequence Number1
Treatment
NON-CORDIS STENT
Patient Age52 YR
-
-